Viewing Study NCT02384395

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-24 @ 1:36 PM
Ignite Modification Date: 2026-01-18 @ 3:14 PM
Study NCT ID: NCT02384395
Status: COMPLETED
Last Update Posted: 2021-11-22
First Post: 2015-03-04
Is Gene Therapy: True
Has Adverse Events: True
Brief Title: Safety and Efficacy of Fixed Dose Combination Dolutegravir/Abacavir/Lamivudine FDC Initiated During Acute HIV Infection
Sponsor: University of North Carolina, Chapel Hill
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None HIV View
None Acute HIV Infection View
Keywords:

Keywords

Keyword Brief Keyword Text View
None Dolutegravir View
None Abacavir View
None Lamivudine View
None acute HIV infection View
None human leukocyte antigen View
None latent HIV reservoir View
None integrase-based regimen View
None viremia View
None antiretroviral therapy View
None fixed dose combination View